Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review

Radiation Oncology

Emmanuel Rio²  Marc-André Mahé²  Francois Paris¹  Stéphane Supiot¹  Mohammed Yahia Almaghrabi² 

[1] INSERM UMR, Nantes-Angers Oncology Research Centre, 8 Quai Moncousu, BP 70721, 44007, Nantes cédex 1, France;Department of Radiation Oncology, Integrated Oncology Centre, BD du Professeur Jacques MONOD, 44805, Saint-Herblain, France

关键词: Surgery;    Radiation biology;    Radiotherapy;    Liver;    Gastrointestinal;    Cancer;   

Others  :  1155506
DOI  :  10.1186/1748-717X-7-126

 received in 2012-02-10, accepted in 2012-07-02,  发布年份 2012

【 摘 要 】

Advances in imaging and biological targeting have led to the development of stereotactic body radiation therapy (SBRT) as an alternative treatment of extracranial oligometastases. New radiobiological concepts, such as ceramide-induced endothelial apoptosis after hypofractionated high-dose SBRT, and the identification of patients with oligometastatic disease by microRNA expression may yet lead to further developments. Key factors in SBRT are delivery of a high dose per fraction, proper patient positioning, target localisation, and management of breathing–related motion. Our review addresses the radiation doses and schedules used to treat liver, abdominal lymph node (LN) and adrenal gland oligometastases and treatment outcomes. Reported local control (LC) rates for liver and abdominal LN oligometastases are high (median 2-year actuarial LC: 61 -100% for liver oligometastases; 4-year actuarial LC: 68% in a study of abdominal LN oligometastases). Early toxicity is low-to-moderate; late adverse effects are rare. SBRT of adrenal gland oligometastases shows promising results in the case of isolated lesions. In conclusion, properly conducted SBRT procedures are a safe and effective treatment option for abdominal oligometastases.

【 授权许可】

   
2012 Almaghrabi et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Kavanagh BD, McGarry RC, Timmerman RD: Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases. Semin Radiat Oncol 2006, 16:77-84.
• [2]Podgorsak EB, Pace GB, Olivier A, Pla M, Souhami M: Radiosurgery with high energy photon beams: A comparison among techniques. Int J Radiat Oncol Biol Phys 1989, 16:857-885.
• [3]Lax I, Blomgren H, Näslund I, Svanström R: Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol 1994, 33:677-683.
• [4]Uematsu M, Shioda A, Tahara K, et al.: Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience. Cancer 1998, 82:1062-1070.
• [5]Benedict SH, Yenice KM, Followill D, et al.: Stereotactic Body Radiation Therapy: The Report of AAPM Task Group 101. Med Phys 2010, 37:4078-4101.
• [6]Hellman S, Weichselbaum RR: Oligometastases. J Clin Oncol 1995, 13:810.
• [7]MacDermed DM, Weichselbaum RR, Salama JK: A rationale for the targeted treatment of oligometastases with radiotherapy. J Surg Oncol 2008, 98:202-206.
• [8]Brenner DJ: The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction. Semin Radiat Oncol 2008, 18:234-239.
• [9]Wolbarst AB, Chin LM, Svensson GK: Optimization of radiation therapy: Integral-response of a model biological system. Int J Radiat Oncol Biol Phys 1982, 8:1761-1769.
• [10]Yeas RJ, Kalend A: Local stem cell depletion model for radiation myelitis. Int J Radiat Oncol Biol Phys 1988, 14:1247-1259.
• [11]Corre I, Niaudet C, Paris F: Plasma membrane signaling induced by ionizing radiation. Mutat Res 2010, 704:61-67.
• [12]Fuks Z, Persaud RS, Alfieri A, et al.: Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res 1994, 54:2582-2590.
• [13]Lee Y, Auh SL, Wang Y, Burnette B, et al.: Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009, 114:589-595.
• [14]Lussier YA, Xing HR, Salama JK, et al.: MicroRNA expression characterizes oligometastasis(es). PLoS One 2011, 6(12):e28650. Epub 2011 Dec 13.
• [15]Yin FF, Das S, Kirkpatrick J, et al.: Physics and imaging for targeting of oligometastases. Semin Radiat Oncol 2006, 16:85-101.
• [16]Potters L, Kavanagh B, Galvin JM, et al.: American Society for Therapeutic Radiology and Oncology; American College of Radiology. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2010, 76:326-732.
• [17]International Commission on Radiation Units and Measurements: Prescribing, recording, and reporting photon beam therapy. Bethesda; 1993. ICRU report, N° 50
• [18]International Commission on Radiation Units and Measurements: Prescribing, recording, and reporting photon beam therapy (supplement to ICRU Report N° 50). Bethesda; 1999. ICRU Report, N° 62
• [19]Ohara K, Okumura T, Akisada M, et al.: Irradiation synchronized with respiration gate. Int J Radiat Oncol Biol Phys 1989, 17:853-857.
• [20]Schefter TE, Kavanagh BD, Timmerman RD, et al.: A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 2005, 62:1371-1378.
• [21]Kataria T, Abhishek A, Chadha P, Janarhan N: Assesment of interfraction set-up uncertainties using X-ray volume imaging (XVI): A guide to adequate 3D PTV margins [abstract]. Radiother Oncol 2010, 96(Suppl):s425.
• [22]Wysocka B, Kassam Z, Lockwood G, et al.: Interfraction and respiratory organ motion during conformal radiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys 2010, 77:53-59.
• [23]Myerson RJ, Garofalo MC, El Naqa I, et al.: Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 2009, 74(3):824-30. Epub 2008 Dec 29.
• [24]Kim CH, Kim H, Beriwal S: Contouring inguinal and femoral nodes: how much margin is needed around the vessels? [abstract]. Int J Radiat Oncol Biol Phys 2011, 81(Suppl 2):s46.
• [25]Van Weieringen N, Kamphuis M, Bel A, Hulshof MCCM: Determination of margins for pelvic lymph nodes for treatment of bladder cancer [abstract]. Int J Radiat Oncol Biol Phys 2011, 81(Suppl 2):s449.
• [26]Play J, Efstathiou JA, Hedgire SS, et al.: Mapping patterns of nodal metastases in seminoma: Rethinking the para-aortic field [abstract]. Int J Radiat Oncol Biol Phys 2011, 81(Suppl 2):s44. (Suppl) abstract 88
• [27]Naisbit M, Sykes J, Brettle D, Magee D, Thwaites DI: A technique for measuring translation and rotation positioning accuracy of automatic table movments using cone beam CT [abstract]. Radiother Oncol 2010, 96(Suppl):s523.
• [28]Ling CC, Humm J, Larson S, et al.: Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000, 47:551-560.
• [29]Aerts HJ, Lambin P, Ruysscher DD: FDG for dose painting: a rational choice. Radiother Oncol 2010, 97:163-164.
• [30]Fong Y, Cohen AM, Fortner JG, et al.: Liver resection for colorectal metastases. J Clin Oncol 1997, 15:938-946.
• [31]Singletary SE, Walsh G, Vauthey JN, et al.: A role for curative surgery in the treatment of selected patients with metastatic breast cancer. Oncologist 2003, 8:241-251.
• [32]Small R, Lubezky N, Ben-Haim M: Current controversies in the surgical management of colorectal cancer metastases to the liver. Isr Med Assoc J 2007, 9:742-747.
• [33]Phillips R, Karnofsky DA, Hamilton LD, Nickson JJ: Roentgen therapy of hepatic metastases. Am J Roentgenol Radium Ther Nucl Med 1954, 71:826-834.
• [34]Topkan E, Onal HC, Yavuz MN: Managing liver metastases with conformal radiation therapy. J Support Oncol 2008, 6(15):9-13.
• [35]Mendez Romero A, Høyer M: Radiation therapy for liver metastases. CurrOpin Support Palliat Care 2012, 6:97-102.
• [36]Krishnan S, Lin EH, Gunn GB, et al.: Conformal radiotherapy of the dominant liver metastasis: a viable strategy for treatment of unresectable chemotherapy refractory cancer liver metastases. Am J Clin Oncol 2006, 29:562-567.
• [37]Pan CC, Kavanagh BD, Dawson LA, et al.: Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 2010, 76(3 Suppl):S94-100.
• [38]Dawson LA, McGinn CJ, Normolle D, et al.: Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable hepatic malignancies. J Clin Oncol 2000, 18:2210-2218.
• [39]Blomgren H, Lax I, Näslund I, Svanström R: Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 1995, 34:861-870.
• [40]Herfarth KK, Debus J, Lohr F, et al.: Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 2001, 19:164-170.
• [41]Wulf J, Hädinger U, Oppitz U, et al.: Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol 2001, 177:645-655.
• [42]Wulf J, Guckenberger M, Haedinger U, et al.: Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol 2006, 45:838-847.
• [43]Hoyer M, Roed H, Traberg Hansen A, et al.: Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 2006, 45:823-830.
• [44]Méndez Romero A, Wunderink W, Hussain SM, et al.: Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol 2006, 45:831-837.
• [45]Kavanagh BD, Schefter TE, Cardenes HR, Stieber VW, Raben D, Timmerman RD, et al.: Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol 2006, 45:848-855.
• [46]Milano MT, Katz AW, Schell MC, Philip A, Okunieff P: Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2008, 72:1516-1522.
• [47]Rusthoven KE, Kavanagh BD, Cardenes H, et al.: Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009, 27:1572-1578.
• [48]Van der Pool AE, Méndez Romero A, Wunderink W, et al.: Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg 2010, 97:377-382.
• [49]Rule W, Timmerman R, Tong L, et al.: Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol 2011, 18(4):1081-7. Epub 2010 Nov 3.
• [50]McCammon R, Schefter TE, Gaspar LE, et al.: Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2009, 73:112-118.
• [51]Bae SH, Kim MS, Cho CK, et al.: High dose stereotactic body radiotherapy using three fractions for colorectal oligometastases. J Surg Oncol 2012. [Epub ahead of print].
• [52]Hasselle MD, Salama JK, Tye KE, et al.: Patterns of progressive following hypofractionated image-guided radiotherapy (HIGRT) to abdominal lymph nodes in oligometastatic (OM) patients [abstract]. Int J Radiat Oncol Biol Phys 2011, 81(Suppl 2):s654.
• [53]Jereczek-Fossa BA, Fariselli L, Beltramo G, Catalano G, Serafini F, Garibaldi C, Cambria R, Brait L, Possanzini M, Bianchi LC, Vavassori A, Zerini D, Orsi F, de Cobelli O, Orecchia R: Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer. Radiother Oncol 2009, 93:14-17.
• [54]Bignardi M, Navarria P, Mancosu P, et al.: Clinical outcome of hypofractionated stereotactic radiotherapy for abdominal lymph node metastases. Int J Radiat Oncol Biol Phys 2011, 81(3):831-8. Epub 2010 Aug 26.
• [55]Choi CW, Cho CK, Yoo SY, et al.: Image-guided stereotactic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer. Int J Radiat Oncol Biol Phys 2009, 74:147-153.
• [56]Kim MS, Yoo SY, Cho CK, et al.: Stereotactic body radiotherapy for isolated para-aortic lymph node recurrence after curative resection in gastric cancer. J Korean Med Sci 2009, 24:488-492.
• [57]Kim MS, Cho CK, Yang KM, et al.: Stereotactic body radiotherapy for isolated paraaortic lymph node recurrence from colorectal cancer. World J Gastroenterol 2009, 15:6091-6095.
• [58]Beitler AL, Urschel JD, Velagapudi SR, Takita H: Surgical management of adrenal metastases from lung cancer. J Surg Oncol 1998, 69:54-57.
• [59]Shen KR, Meyers BF, Larner JM, Jones DR, American College of Chest Physicians: Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132(3 Suppl):290S-305S.
• [60]Porte HL, Roumilhac D, Graziana JP, et al.: Adrenalectomy for a solitary adrenal metastasis from lung cancer. Ann Thorac Surg 1998, 65:331-335.
• [61]Higashiyama M, Doi O, Kodama K, Yokouchi H, Imaoka S, Koyama H: Surgical treatment of adrenal metastasis following pulmonary resection for lung cancer: comparison of adrenalectomy with palliative therapy. Int Surg 1994, 79:124-135.
• [62]Chawla S, Chen Y, Katz AW, et al.: Stereotactic body radiotherapy for treatment of adrenal metastases. Int J Radiat Oncol Biol Phys 2009, 75:71-75.
• [63]Holy R, Piroth M, Pinkawa M, Eble MJ: Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther Onkol 2011, 187:245-251.
• [64]Casamassima F, Livi L, Masciullo S, et al.: Stereotactic radiotherapy for adrenal gland metastases: university of Florence experience. Int J Radiat Oncol Biol Phys 2012, 82:919-923.
• [65]Scorsetti M, Alongi F, Filippi AR, et al.: Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: A retrospective analysis of 34 patients. Acta Oncol 2012, 51(5):618-623.
• [66]Arnaud A, Caiazzo R, Claude L, Zerrweck C, Carnaille B, Pattou F, Carrie C: Stereotactic Body radiotherapy vs surgery for treatment of isolated adrenal metastases: A matched pair analysis including 62 patients [abstract]. Int J Radiat Oncol Biol Phys 2011, 81(Suppl 2):s89.
• [67]Kao J, Packer S, Vu HL, et al.: Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer 2009 Aug 1, 115(15):3571-80.
• [68]Almaghrabi MY, Rio E, Mahé M, et al.: Stereotactic Body Radiation Therapy (SBRT) with concomitant chemotherapy (Campto) for lung and liver metastases of colorectal cancer (CRC): Preliminary results of a prospective Phase II multicenter study [abstract]. Int J Radiat Oncol Biol Phys 2011, 81(Suppl 2):s367.